At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 57 target
Drug / intervention
concurrent chemotherapy +1 moredrug
Likely dose
concurrent chemotherapy 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Phase Ⅱ Study of Split-course Chemoradiotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection
In Brief
A Phase 2 clinical trial evaluating split-course radiotherapy and concurrent chemotherapy for Non-small Cell Lung Cancer. Targeting 57 participants across 1 site.
Detailed Summary
This Phase II randomized study is to determine the efficacy of split-course irradiation with concurrent chemotherapy in locoregional recurrence of non-small cell lung cancer after surgical resection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedDec 2016
Primary CompletionJun 2020
Study CompletionJul 2021
TodayJul 2026
First PostedDec 30, 2016
Enrollment StartAug 1, 2015
Primary CompletionJun 1, 2020
Study CompletionJul 1, 2021
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 9.5 years ago
Interventions
split-course radiotherapyradiation
split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
concurrent chemotherapydrug
weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation